Drug · CHEMBL3

NICOTINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. NICOTINE. Drugs and targets, record CHEMBL3. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: NICOTINE; ChEMBL
ChEMBL ID: CHEMBL3; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Habitrol, Nicabate, Nicoderm cq, Nicopass, Nicopatch, Nicorette invisi, Nicotinell classic, Nicotinell support, Nicotinell tts 10, Nicotinell tts 20, Nicotinell tts 30, Nicotrol, Nicotrol inhaler, Nicotrol ns, Niquitin, Niquitin clr, Niquitin minis cherry, Niquitin minis mint, Niquitin minis orange, Niquitin mint, Niquitin pre-quit, Niquitin strips mint, Prostep, Stoppers, Stubit; ChEMBL
Other form: NICOTINE BITARTRATE, CHEMBL3989563; Drugs and targets
Other form: NICOTINE POLACRILEX, CHEMBL1201536; Drugs and targets
DrugBank: DB00184; DrugBank
InChIKey: SNICXCGAKADSCV-JTQLQIEISA-N; ChEMBL
Open Targets' highest stage: Approval, for 1 of its 55 diseases, from ATC and TTD; Open Targets

Targets2

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	Neuronal acetylcholine receptor; alpha4/beta2 agonist	AGONIST	https://conductscience.org/library/genes/1137
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	Neuronal acetylcholine receptor; alpha4/beta2 agonist	AGONIST	https://conductscience.org/library/genes/1141

Source ChEMBL

Diseases55

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
nicotine dependence	Approval	ATC and TTD	254	250	https://conductscience.org/library/drugs?q=MONDO_0008575
smoking cessation	Phase 3	ClinicalTrials.gov	76	76	https://conductscience.org/library/drugs?q=EFO_0004319
smoking behavior	Phase 3	ClinicalTrials.gov	73	73	https://conductscience.org/library/drugs?q=EFO_0004318
major depressive disorder	Phase 3	ClinicalTrials.gov	11	11	https://conductscience.org/library/drugs?q=MONDO_0002009
schizophrenia	Phase 2	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=MONDO_0005090
lung cancer	Phase 2/3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0008903
Cognitive impairment	Phase 2	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=HP_0100543
depressive disorder	Phase 2	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0002050
Parkinson disease	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0005180
HIV infectious disease	Phase 2/3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005109

1 to 10 of 55Source Open Targets

See all 55 diseases

Trials665

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 21 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 11 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00356993	Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP)		6,009	2019-05-02	nicotine	Its name	ClinicalTrials.gov
NCT01574703	Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.	Phase 4	4,595	2016-12-29	nicotine	Its name	ClinicalTrials.gov
NCT00851357	Telephone Counseling and the Distribution of Nicotine Patches to Smokers	Phase 3	4,200	2020-02-10	nicotine	Its name	ClinicalTrials.gov
NCT01502306	A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline	Phase 3	3,816	2019-10-01	nicotine	Its name	ClinicalTrials.gov
NCT01736085	Providing Free Nicotine Patches to Quitline Smokers	Phase 3	3,706	2020-02-19	nicotine	Its name	ClinicalTrials.gov
NCT00775944	Trial Comparing Different Methods of Support With Stopping Smoking (PORTSSS/Stop Together Trial)	Phase 4	2,591	2012-10-26	nicotine	Its name	ClinicalTrials.gov
NCT00534404	A Randomized Trial of Internet Access to Nicotine Patches		2,485	2015-02-03	nicotine	Its name	ClinicalTrials.gov
NCT00352781	Stop Smoking Therapy for Ontario Patients		1,767	2012-04-17	nicotine	Its name	ClinicalTrials.gov
NCT00332644	Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms	Phase 4	1,504	2011-11-30	nicotine	Its name	ClinicalTrials.gov
NCT03603496	Post-Discharge Smoking Cessation Strategies: Helping HAND 4	Phase 4	1,416	2022-05-05	nicotine replacement therapy	Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers	ClinicalTrials.gov

1 to 10 of 665

See all 665 trials

Comparisons in its trials380

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Proactive Group vs Reactive Group: serious adverse events	16 of 649	6 of 649	1,298	NCT00632411	Trial comparisons
Nicotine vs Placebo: serious adverse events	20 of 597	14 of 601	1,198	NCT02355665	Trial comparisons
Proactive Group vs Reactive Group: Continuous Abstinence	173 of 521	136 of 529	1,050	NCT00632411	Trial comparisons
Opt Out vs Opt In: deaths from any cause	27 of 655	19 of 345	1,000	NCT02721082	Trial comparisons
Opt Out vs Opt In: serious adverse events	191 of 655	89 of 345	1,000	NCT02721082	Trial comparisons
Intervention vs Control: Number of Participants With Self-reported Tobacco Abstinence in Past 7 Days	95 of 482	79 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants With Self-reported Use of NRT in Past Week/Month	92 of 482	86 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants With Self-reported Quit Attempt	214 of 482	153 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants With Self-reported Tobacco Abstinence in Past 7 Days	104 of 482	92 of 352	834	NCT03717051	Trial comparisons
Intervention vs Control: Number of Participants Who Enroll in Any Smoking Cessation Service in Hong Kong	156 of 482	158 of 352	834	NCT03717051	Trial comparisons

1 to 10 of 380

See all 380 comparisons in its trials

Papers from its trials442

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42096636	RESULT	1	PubMed
39477130	RESULT	1	PubMed
37889541	RESULT	1	PubMed
34029565	RESULT	1	PubMed
33089005	RESULT	1	PubMed
32578165	RESULT	1	PubMed
31515173	RESULT	1	PubMed
31241286	RESULT	1	PubMed
30932386	RESULT	1	PubMed
30874290	RESULT	1	PubMed

1 to 10 of 442

See all 442 papers from its trials

Tests in its trials28

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Continuous Performance Test	9	5	ConductCognition
Purchase Task	8	3	ConductCognition
1-Back Task	7	3	ConductCognition
2-Back Task	6	3	ConductCognition
Stroop Color-Word Test	6	5	ConductCognition
Go/No-Go Task	5	3	ConductCognition
Food Cue Reactivity Task	4	3	ConductCognition
Rapid Visual Information Processing	4	4	ConductCognition
Selective Reminding Task	4	0	ConductCognition
Symbol Coding	4	0	ConductCognition

1 to 10 of 28

See all 28 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL3

GET https://conductscience.org/api/drugs/v1/CHEMBL3/diseases?page=2

API reference For AI assistants